Pfizer, Scripps Sue to Block Copy of ‘Most Expensive’ Heart Drug

Pfizer Inc. and the Scripps Research Institute allege in a new lawsuit that a copy of Vyndamax proposed by Dexcel Pharma Technologies Ltd. infringes three patents for the blockbuster heart drug, an increasingly important source of Pfizer’s revenue.

Pfizer and Scripps “together own all substantial rights” to the patents, according to a complaint filed Thursday in the US District Court for the District of Delaware. Two were assigned to Scripps and one to Pfizer.

Vyndamax is used to reduce the risk of death and hospitalization from a rare heart condition called transthyretin amyloid cardiomyopathy, or ATTR-CM. The disease is ...